4.36 USD
▲+0.24+1.04%
盘后 4.31 -0.12%
2026-08-03
市值
$1.95B
市盈率
—
EPS
-0.93
股息率
—
52 周区间
1.76 – 5.64
成交量
10.68M
Beta
0.69
目标价
8.80
52W 低 1.7652W 高 5.64
价格走势
公司简介
Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanomal; and Proleukin, an interleukin-2 product for the treatment of patients w...